Dezhan HealthCare Co Ltd

Dezhan Health released its 2026 interim report. The company's total operating revenue was 143 million yuan, down 14.26% year-on-year. Net profit attributable to the parent company was a loss of 58.1986 million yuan, with the loss widening year-on-year. Net cash flow from operating activities was a negative 52.2939 million yuan, down 288.09% year-on-year. The company's asset-liability ratio was 5.70%, gross margin was 37.11%, ROE was negative 1.27%, and diluted earnings per share was negative 0.03 yuan. The number of shareholders was 50,900, and the top ten shareholders held 48.97% of the total share capital.

Dezhan Health disclosed that the entire stake held by shareholder Chen Zhiwenlong, who owns more than 5% of the company, has been frozen. The number of shares frozen this time is approximately 130 million, accounting for 100% of his holdings and 6.18% of the company's total share capital. The company stated that Chen Zhiwenlong is not a controlling shareholder or actual controller, and this freeze will not affect daily operations and management.

Dezhan Health has released its 2026 semi-annual performance forecast, expecting a net loss attributable to shareholders of 38 million to 75 million yuan for the first half, compared with a loss of 42.9265 million yuan in the same period last year. The company stated that the loss is mainly due to the continued deepening of its business structure integrating pharmaceuticals, medical services, and health, increased investment in innovative research and development, and the impact of volume-based procurement policies on revenue.